- Home
- CRVO vs GUTS Comparison
CRVO vs GUTS Comparison
Compare CRVO & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- GUTS
- Stock Information
- Founded
- CRVO 2001
- GUTS 2010
- Country
- CRVO United States
- GUTS United States
- Employees
- CRVO N/A
- GUTS N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- CRVO Health Care
- GUTS
- Exchange
- CRVO Nasdaq
- GUTS NYSE
- Market Cap
- CRVO 67.4M
- GUTS 58.8M
- IPO Year
- CRVO N/A
- GUTS 2024
- Fundamental
- Price
- CRVO $6.96
- GUTS $1.52
- Analyst Decision
- CRVO Strong Buy
- GUTS Buy
- Analyst Count
- CRVO 7
- GUTS 1
- Target Price
- CRVO $19.33
- GUTS $10.00
- AVG Volume (30 Days)
- CRVO 162.5K
- GUTS 786.6K
- Earning Date
- CRVO 08-08-2025
- GUTS 08-13-2025
- Dividend Yield
- CRVO N/A
- GUTS N/A
- EPS Growth
- CRVO N/A
- GUTS N/A
- EPS
- CRVO N/A
- GUTS N/A
- Revenue
- CRVO $9,308,215.00
- GUTS $60,000.00
- Revenue This Year
- CRVO N/A
- GUTS N/A
- Revenue Next Year
- CRVO N/A
- GUTS N/A
- P/E Ratio
- CRVO N/A
- GUTS N/A
- Revenue Growth
- CRVO 15.14
- GUTS N/A
- 52 Week Low
- CRVO $1.80
- GUTS $0.87
- 52 Week High
- CRVO $20.63
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- CRVO 51.63
- GUTS 41.63
- Support Level
- CRVO $5.45
- GUTS $1.47
- Resistance Level
- CRVO $7.55
- GUTS $1.68
- Average True Range (ATR)
- CRVO 0.59
- GUTS 0.14
- MACD
- CRVO 0.14
- GUTS -0.03
- Stochastic Oscillator
- CRVO 75.71
- GUTS 9.80
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.